A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 21, 2022

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions

Renal Impairment

Interventions

DRUG

AZD4831

Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.

Trial Locations (1)

Research Site, Sofia